EUCTR2005-003354-10-GB进行中（未招募）1 期
A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered AF37702 Injection (HematideTM) in Anemic Cancer Patients Receiving Chemotherapy - AFX01-05
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •The subject has signed a written, witnessed informed consent. Males or females, including women of childbearing potential on a highly effective method of birth control, age 18 - 80 years. Hemoglobin =8 and < 11 g/dL within 1 week prior to administration of study drug in patients who will receive at least 9 weeks of myelosuppressive chemotherapy for a histologically confirmed solid tumor malignancy or lymphoma. ECOG performance status 0-2. Within 4 weeks prior to study drug administration, one transferrin saturation =20%, serum or red cell folate level and one serum vitamin B12 level above the lower limit of normal. One reticulocyte hemoglobin content (CHr) > 29 pg within 4 weeks prior to study drug administration. Within 1 week prior to study drug administration, one absolute neutrophil count = 1.0 x10^9/L and one platelet count =75 x10^9/L. Life expectancy > 6 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Treatment with any erythropoiesis stimulating agent (ESA) in the past 90 days, history of failure to respond to ESA treatment, known antibodies to other ESAs or history of PRCA. Acute or chronic leukemia, myelodysplastic syndrome or multiple myeloma, previous or planned radiotherapy to more than 50% of either the pelvis or spine. Known intolerance to parenteral iron supplementation, RBC transfusion within 4 weeks prior to study drug administration, known hemoglobinopathy or hemolysis. History of pulmonary embolism or DVT in the previous 2 years or current therapeutic doses of anticoagulants. Known blood loss as a cause of anemia, uncontrolled or symptomatic inflammatory disease, AST or ALT > 2.5 times the upper limit of normal or > 5 times the upper limit of normal if liver metastases are present, creatinine > 175 µmol/L. History of bone marrow or peripheral blood cell transplantation, pyrexia/fever of = 39 °C within 48 hours prior to study drug administration, poorly controlled hypertension, epileptic seizures, advanced CHF (NYHA Class IV), likelihood of early withdrawal or interruption of study due to conditions such as of MI within the past 3 months, severe or unstable coronary artery disease, stroke, respiratory, autoimmune, neuropsychiatric or neurological abnormalities, liver disease including active hepatitis B and hepatitis C, active HIV disease, or other diseases within the past 6 months that may interfere with patient assessment or follow-up. Anticipated elective surgery during the study period, history of multiple drug allergies, exposure to any investigational agent within 1 month prior to administration of study drug or planned receipt during the study.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered AF37702 Injection (HematideTM) in Anemic Cancer Patients Receiving Chemotherapy - AFX01-05Anemia in cancer patients receiving chemotherapy.EUCTR2005-003354-10-CZAffymax, Inc.90
进行中（未招募）
1 期
An early phase study which aims to find a dose, asses safety and tolerability of AKN-028 in Patients with Acute Myelogenous Leukemia (AML)Acute Myelogenous Leukemia (AML)MedDRA version: 14.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2011-003285-33-GBAkinion Pharmaceuticals AB25
进行中（未招募）
1 期
An early phase study which aims to find a dose, asses safety and tolerability of AKN-028 in Patients with Acute Myelogenous Leukemia (AML)Acute Myelogenous Leukemia (AML)MedDRA version: 17.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2011-003285-33-SEAkinion Pharmaceuticals AB55
进行中（未招募）
1 期
An early phase study which aims to find a dose, asses safety and tolerability of AKN-028 in Patients with Acute Myelogenous Leukemia (AML)Acute Myelogenous Leukemia (AML)MedDRA version: 17.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2011-003285-33-CZAkinion Pharmaceuticals AB55
进行中（未招募）
不适用
An early phase study which aims to find a dose, asses safety and tolerability of AKN-028 in Patients with Acute Myelogenous Leukemia (AML)Acute Myelogenous Leukemia (AML)MedDRA version: 17.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2011-003285-33-PLAkinion Pharmaceuticals AB55